How Do Patients Experience Individualized Medicine? A Qualitative Interview-based Study of Gene Expression Analyses in the Treatment of Breast Cancer by Schleidgen, Sebastian et al.
How Do Patients Experience Individualized Medicine?
A Qualitative Interview-based Study of Gene Expression Analyses
in the Treatment of Breast Cancer
Wie erleben Patientinnen individualisierte Medizin?
Eine qualitative Interviewstudie zum Beispiel der Genexpressions-
analysen bei der Mammakarzinombehandlung
Authors
Sebastian Schleidgen1*, Sandra Thiersch2*, Rachel Wuerstlein3,4, Georg Marckmann2
Affiliations
1 Pflegewissenschaftliche Fakultät, Philosophisch-
Theologische Hochschule Vallendar, Vallendar, Germany
2 Institut für Ethik, Geschichte und Theorie der Medizin,
Ludwig-Maximilians-Universität München, München,
Germany
3 Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Brustzentrum der Universität München, München,
Germany
4 Comprehensive Cancer Center LMU München, München,
Germany
Key words
joint decision‑making, gene expression analyses,
medical benefit, molecular genomic individualization
Schlüsselwörter
gemeinsame Entscheidungsfindung, Genexpressionsanalyse,
medizinischer Nutzen, molekulargenetische Individualisie-
rung
received 5.5. 2017
revised 27.6. 2017
accepted 30.6. 2017
Bibliography
DOI https://doi.org/10.1055/s-0043-115396
Geburtsh Frauenheilk 2017; 77: 984–992 © Georg Thieme
Verlag KG Stuttgart · New York | ISSN 0016‑5751
Correspondence
Sandra Thiersch
Institut für Ethik, Geschichte und Theorie der Medizin,
Ludwig-Maximilians-Universität München
Lessingstraße 2, 80336 München, Germany
sandra.thiersch@med.uni-muenchen.de
Deutsche Version unter:
https://doi.org/10.1055/s-0043-115396
ABSTRACT
Introduction In recent years, the hopes and expectations as-
sociated with so-called individualized medicine have been the
subject of intense debate as has the medical potential of this
approach. Questions about the uses of gene expression anal-
yses for decisions on adjuvant systemic treatment options for
patients with breast cancer have played a prominent role in
this debate. There are a number of empirical studies on the
effect of gene expression tests on the therapy decisions of
physicians and the potentially conflicted decisions for pa-
tients. Very little attention has been paid to how patients per-
ceive such approaches, the extent to which they feel included
in the therapy decision, and the expectations they associate
with such an approach.
Material and Methods Using qualitative explorative inter-
views, the study looked at how well patients with breast can-
cer understood the individualized treatment approaches and
examined patientsʼ experiences and expectations with regard
to gene expression analyses. The sample consisted of 8 pa-
tients who were diagnosed with primary hormone receptor-
positive, HER2-negative breast cancer between 2013 and
2014 and who underwent gene expression analyses as part
of their adjuvant therapy planning.
Results Patients were found to have a quite realistic view of
the benefits of gene expression analyses, although it also be-
came clear that the treatment could also raise false hopes.
The statements by the interviewed women also illustrated
the necessity of continuing to explore the possibilities and
limits to joint decision-making in such complex medical con-
texts as individualized molecular genomic medicine. And fi-
nally, the interviews reflected the hope for individualized
treatment in the broadest sense of the word.
Conclusion The results of the study highlight the challenge
of taking psychosocial aspects of medical treatment suffi-
ciently into consideration, given the ever increasing options
for molecular genomic individualization.
* Shared first authorship
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ZUSAMMENFASSUNG
Einleitung Die mit der sogenannten individualisierten Medi-
zin verbundenen Hoffnungen und Erwartungen sind seit eini-
gen Jahren ebenso Gegenstand intensiver Debatten wie ihr
medizinisches Potenzial. Prominent ist in diesem Zusammen-
hang die Frage nach dem Nutzen von Genexpressionsana-
lysen zur Entscheidung über adjuvante Systemtherapieoptio-
nen bei Mammakarzinompatientinnen. Zwar gibt es eine Rei-
he empirischer Untersuchungen zum Einfluss der Ergebnisse
von Genexpressionstests auf ärztliche Therapieentscheidun-
gen sowie möglicherweise auftretende Entscheidungskonflik-
te bei Patienten. Kaum erforscht wurde bislang allerdings, wie
Patienten solche Ansätze wahrnehmen, wie sie sich in ent-
sprechende Therapieentscheidungen einbezogen fühlen und
welche Erwartungen sie mit solchen Ansätzen verbinden.
Material und Methoden Vor diesem Hintergrund wurde an-
hand qualitativ-explorativer Interviews das Verständnis von
Brustkrebspatientinnen über individualisierte Behandlungs-
ansätze sowie ihre Erlebnisse und Erwartungen in Bezug auf
die Durchführung von Genexpressionsanalysen untersucht.
Die Stichprobe bestand aus 8 Patientinnen, bei denen zwi-
schen 2013 und 2014 ein primäres, hormonrezeptorpositives,
HER-2-negatives Mammakarzinom festgestellt wurde und die
sich im Rahmen ihrer adjuvanten Therapieplanung einer Gen-
expressionsanalyse unterzogen hatten.
Ergebnisse Dabei zeigte sich eine durchaus realistische Auf-
fassung der Möglichkeiten von Genexpressionanalysen, auch
wenn deutlich wurde, dass das Behandlungskonzept auch fal-
sche Hoffnungen wecken kann. Die Aussagen der Inter-
viewpartnerinnen verdeutlichten darüber hinaus die Notwen-
digkeit, Möglichkeiten und Grenzen gemeinsamer Entschei-
dungsfindung in komplexen medizinischen Zusammenhän-
gen wie der molekulargenetisch-individualisierten Medizin
weiter auszuloten. Und schließlich zeigte sich in den Inter-
views die Hoffnung auf eine im umfassenden Sinne individua-
lisierte Behandlung.
Schlussfolgerung Damit verdeutlichen die Ergebnisse der
Studie die Herausforderung, angesichts stetig zunehmender
Möglichkeiten molekulargenetischer Individualisierung auch
die psychosozialen Aspekte medizinischer Behandlung ange-
messen zu berücksichtigen.
1 Where applicable, the following sections always refer equally to persons
of all genders. However, in the interests of readability, only the feminine
or masculine form is used, depending on the context.Introduction
In recent years, the hopes and expectations – particularly of pa-
tients – associated with so-called individualized medicine (IM)
have been the subject of intense debates [1, 2]. The primary ques-
tion is whether and to what extent the expectations of the individ-
ual patient that IM will regard him1 as an individual are justified. If
nothing else, these discussions are the result of the sometimes
strongly divergent scientific and medical assessment of the po-
tential of IM. There is one standpoint which believes that compre-
hensive use of IM would not only make healthcare more effective
and efficient, it would also allow care to be adapted to the individ-
ual wishes and needs of the respective patient [3–9]. But it has also
been suggested that IM is a ‘hype’ promoted by the economic in-
dustrial interests, that its real potential is overrated and, not least,
that it raises unrealistic hopes in patients [10–12]: IM is “medicine
based on molecular genomic properties and has nothing to do
with medicine directed towards the individual patient. Any ‘indi-
vidualization’ only occurs at the molecular genomic level, not at
a personal level between physician and patient” ([12]: p. 236).
A closer inspection of how the term is actually used shows that
IM is generally understood to mean medicine “which attempts to
improve the stratification and timing of healthcare provision
through the use of biomarkers at the level of the molecular signal-
ing pathways and of genomics, proteomics and metabolomics”
([13]: p. 226, [14,15]). The statement that IM only individualizes
at the molecular genomic level therefore appears to be absolutely
correct [2, 16].
Nevertheless it is important to have a nuanced view of the po-
tential of IM and its focus on molecular genomics [2,17]. To take a
paradigmatic example, gene expression analyses can assist in the
decision on adjuvant systemic therapy for patients with breast
cancer [18]. The subgroup of patients with primary hormone re-Schleidgen S et al. How Do Patients… Geburtsh Frauenheilk 2017; 77: 984–992ceptor-positive, HER2-negative breast cancer represents a special
case in point: around 80% of these patients do not require adju-
vant chemotherapy to prevent recurrence [19]. The problem is
that it is not possible to give clear recommendations for or against
adjuvant chemotherapy for this subgroup based on established
factors (e.g., patient age or lymph node status) [20]. However, in
recent years various genes have been identified, principally in tu-
mor tissue, whose level of expression and activities allow predic-
tive statements to be made about the benefit of adjuvant chemo-
therapy for these patients. The level of expression and the activ-
ities can be investigated using gene expression tests such as
Oncotype DX, EndoPredict, Mammaprint or Prosigna, thus – ac-
cording to the proponents of these tests – providing the basis for
reliable therapeutic recommendations [21–25]. While both na-
tional and international guidelines recommend performing such
tests (www.ago-online.de), the Institute for Quality and Efficiency
in Healthcare (IQWiG) has recently stated that the benefits of such
strategies are not currently proven [20].
This raises the question whether, given what is actually possi-
ble, the hopes and expectation created by molecular genomic indi-
vidualized medicine, such as the option of avoiding chemotherapy
to the benefit of the patient, will not be disappointed. More spe-
cifically, the question is whether and to what extent joint decision-
making by the physician and the patient is even possible given the
complex medical-biological mechanisms and the necessity of
making each decision on a case-by-case basis. There are a number
of empirical studies on the impact of gene expression tests on
therapeutic decisions taken by physicians and on potentially con-985
GebFra Science |Original Articleflicted decisions by patients [26,27]. But, especially in the context
of decisions about adjuvant chemotherapy in patients with pri-
mary hormone receptor-positive, HER2-negative breast cancer,
there has not been much research into
▪ how patients perceive such individualized molecular genomic
approaches and the therapeutic decisions based on the find-
ings,
▪ to what extent patients feel that they are involved in the ther-
apy decision, and
▪ what hopes and expectations they associate with such ap-
proaches.
Examining these perspectives is highly important to ensure an
ethically appropriate management of the new opportunities cre-
ated by biomarker-based, stratified medicine, particularly for
making autonomous decisions in the context of shared decision-
making. This study therefore aimed to investigate how well pa-
tients with primary hormone receptor-positive, HER2-negative
breast cancer understood individualized treatment approaches
and to examine patientsʼ hopes and expectations of gene expres-
sion analyses, using qualitative explorative interviews.Material and Methods
Recruitment
Patients diagnosed with primary, hormone receptor-positive,
HER2-negative breast cancer and who had undergone gene ex-
pression analyses as part of adjuvant therapy planning were se-
lected for recruitment into the study. Study participants were re-
cruited by physicians from the Breast Center of Munich University
Hospital. Recruitment was done over a period of about one-and-a-
half years. An appointment for an interview was made with those
patients who agreed to voluntarily participate in the study and
had signed the consent form. All interviews were carried out in
the patientsʼ domestic setting. The interview-based study was ap-
proved by the Ethics Committee of Ludwig Maximilians University
(Project No. 262-13, letter dated July 2, 2013).
Sample
A sample of eight patients who had been diagnosed with breast
cancer between 2013 and 2014 were recruited into the study. All
of the interviewed patients were treated in the Breast Center of
Munich University Hospital. For 6 patients, the first physician to
treat them was a physician from the Breast Center, 2 further pa-
tients switched to the Breast Center after they had received their
diagnosis. Three patients participated in the ADAPT study [28], 3
other patients participated in the German Breast Cancer Intrinsic
Subtype study (BCIST) [27]. Two patients were unable to partici-
pate in either of the studies because of diagnostic problems.
At the time of the interview the tumor had been surgically re-
moved in all patients. Adjuvant therapy planning depended on
the findings of gene expression analyses. Three patients were
undergoing chemotherapy at the time of the interview and had
already completed half of their chemotherapy cycles. Three other
patients had started radiotherapy. Two patients had undergone986breast amputation, which was not followed by further treatment
(▶ Table 1).
Data collection
Data were collected using guided, partly structured interviews
which were carried out in the period from August 2014 to March
2015 by an interviewer who was not part of the treatment team
(SS). Questions were devised as open questions to allow the inter-
viewed patients sufficient leeway for their own responses. The in-
terviews were carried out as personal interviews and took be-
tween 33 and 55 minutes. Great importance was attached to en-
suring that the interview was carried out in a low stress environ-
ment.
The interview guidelines were based on the literature and de-
veloped after discussion with the relevant experts from the field of
oncology; the interviews covered five topics:
1. a description of the patientʼs medical history,
2. the patient briefing and the decision whether or not to under-
go gene expression analyses,
3. how the decision for further treatment was based on gene ex-
pression analyses,
4. the patientʼs perception of the further treatment, and
5. the significance of the findings of gene expression analyses for
the patient and third persons.
The interviews were digitally recorded, anonymized and tran-
scribed word for word in accordance with the rules developed by
Kuckartz [29].
Data analysis
The transcripts were analyzed with the help of the MAXQDA 12
software program according to the rules for qualitative content
analysis described by Mayring [30]. The goal was to reduce the
quantity of existing material to what was essential for the research
questions. The first step consisted of developing theory-guided
topics for the set of categories. The second step consisted of de-
fining the selection and abstraction criteria for creating the cate-
gories. Then, in a third step, inductive main and sub-categories
and the characteristics of the individual topic areas were created.
The fourth step consisted of defining the categories and providing
them with typical examples.
Steps 2 and 3 (determination of selection and abstraction lev-
els, working through the material, formulation of the categories,
summarization) was initially done for two interviews and then re-
peated until the individual categories could be clearly differenti-
ated from one another and the text passages could be unequivo-
cally assigned to categories (step 4). After completing this first
processing cycle the categories were applied to the remaining six
interviews.
The results of the first four steps were interpreted in a fifth and
final step in the light of our research questions and discussed with
social science colleagues at a research colloquium.Schleidgen S et al. How Do Patients… Geburtsh Frauenheilk 2017; 77: 984–992
▶ Table 1 Exemplary excerpts from the set of categories: theory-guided topics, deduced main categories and subcategories, typical examples and
definitions.
Topics Main cate-
gory
Subcategory Variable Typical example Definition
Understanding
of “individual-
ized medicine”
Perception
of treatment
received
Medical
aspects
Type of
medication
“Everyone is given something else, well I havenʼt
yet been able to work that out properly yet.
My hubby says a lot but somehow everyone still
seems to be given something else, at least, the
little bags always look different.” (RESP 2)
Statement on the extent to
which treatment is perceived
as being tailored to each re-
spective patient (type of medi-
cation, medical treatment)
Reasons for
perception
Choice of
several treat-
ment options
“The three physicians, that is, the radiologists and
the senior physician, got together and explained
what the options are to me.” (RESP 6)
Statements of patients why
they perceived the treatment
as tailored or not tailored to
their needs
Perceptions of
gene expres-
sion analyses
Assessment of
gene expres-
sion analyses
Positive
assessment
Appropriate
therapy can
be found
“So when the diagnosis is there, if I can put it that
way, and there is the option of having such tests
before you start treatment to find out how your
body is likely to respond, I think that is a good
option: to find the tailored treatment for yourself.
And not just simply impose a sort of one-type-
fits-all treatment.” (RESP 4)
Positive and negative assess-
ment of gene expression
analyses by patients
Expectations
about the
course of
treatment
Expectations
about the
course of
treatment
Schedule Near-term
appointments
“And so I got an appointment immediately for the
very next day.” (RESP 7)
Statements on the expecta-
tions of patients about the
course of treatment (schedule
and medical procedures, etc.)
Wishes and
suggestions
for improve-
ment
(Psychological)
support for
family
members
“And I also think, at least thatʼs how I feel, that it
puts a big strain on familymembers. (…). The kids
arenʼt stressed that much but my husband, for
example, is really suffering. And I donʼt know
what could be done to improve matters, so that
they would simply, that they would also be sup-
ported or, yeah.” (RESP 5)
Statements on wishes and
suggestions for improvement
made by patients about the
course of treatment
Involvement in
the patient
briefing and in
the decision
about further
treatment
Developing
the treatment
decision
Making the
decision
Patient “So then it was my decision, the decision was in
my hands. I was told that if I could live with this
figure of 13%, then weʼll only do the radiation,
then you have made the decision. From amedical
perspective we would suggest that you do this
and that.” (RESP 4)
Statements on how the deci-
sion for or against a therapy
was made
Patient brief-
ing about gene
expression
analyses
Positive assess-
ment of the
patient brief-
ing received
Explanations of
the Oncotype
DX test by
physicians
were compre-
hensible
“Well I thought to myself that they are doing it
well and they are doing it carefully and that is the
right thing for me now. I was also able to under-
stand how the decision is made.” (RESP 5)
Perceptions and information
about gene expression analy-
ses and assessment of the in-
formationResults
Below we present the results for the topic areas “Understanding
of individualized medicine”, “Perceptions of gene expression anal-
yses”, “Expectations about the course of treatment” and “Involve-
ment in the patient briefing and the decision about further treat-
ment” (▶ Table 1). The sources (RESP) refer to the respective
cited respondent.
Understanding of individualized medicine
Patients were asked about what they understood individualized
treatment to mean and whether they perceived gene expression
analyses as a part of such a treatment strategy. Seven patients re-
ported that in their view individualized treatment would consist ofSchleidgen S et al. How Do Patients… Geburtsh Frauenheilk 2017; 77: 984–992different treatment options. Chemotherapy, for example, was
viewed by these patients as a form of treatment which was often
administered regardless of the assessment about its specific ben-
efit and was therefore not considered to be a form of individual-
ized treatment.
During that time I talked with several women […] They happened
to be in hospital in A. The hospital had a kind of general program
for these women. And these women also had hormonally active
tumors. But no one asked: is that necessary? Does chemotherapy
actually offer benefits or are the women suffering more harm than
any benefit they could get from it, because chemotherapy does not
achieve more than this anti-hormone therapy? (RESP 1)987
GebFra Science |Original ArticleThree patients viewed gene expression analyses as part of the di-
agnostics required for tailored treatment, with drug therapy sub-
sequently tailored to the respective patient and her tumor type. In
this context one participant reported that they had found out dur-
ing talks with other patients that each patient was getting a differ-
ent drug (RESP 2). Another patient reported that extensive medi-
cal tests and examinations had been carried out to confirm her di-
agnosis and obtain a better assessment of the benefit of further
treatment options (RESP 5).
Four patients perceived gene expression analyses as part of
stratified treatment, but expressed doubts about whether the
treatment really was tailored. They justified their statement by
pointing out that it was impossible to administer treatment tai-
lored to every individual person. But they also held the view that
there were different types of breast cancer and therefore there
were different groups of patients who required different specific
drugs.
Well, I think that it is not possible to give tailored treatment to
every individual person. […] But I have the feeling that patients
who do have such a hormonally regulated tumor, that they are
sort of in the same boat, and that at that moment in time treat-
ment is tailored to me when they say: “okay, in your case, if we can
say that the cause is hormonal, then you need surgery and before
that anti-hormone therapy, that is where you are at.” But that
doesnʼt mean that this only applies to me. I just believe that there
are many patients who are in the same boat. And I also think, and
that is also what I was told, that I did not get a chemotherapy
specially tailored to me but that patients who take the path of
anti-hormone treatment, then surgery and then find out that they
still have to have chemotherapy, that they get the same drugs,
adjusted according to age, blood counts and weight. Thatʼs how I
would see it. (RESP 4)
The same patient also stated that in her view no tailored therapy
existed. She justified her opinion with the statement that for her a
tailored therapy would be a treatment with 100% chance of cure
(RESP 4).
Assessment of gene expression analyses
The assessment of gene expression analyses by patients was gen-
erally positive: getting treatment from a hospital which offered
such analyses was considered to be an advantage.
And then I just thought: “My God, I am so lucky to have got in
there and got the benefit of these new, modern insights.” (RESP 1)
In the same context one patient criticized the fact that gene ex-
pression analyses were not available in every hospital, partly be-
cause treating physicians questioned how useful they were (RESP
8). The interviewed patients primarily justified their positive as-
sessment by the fact that gene expression analyses provided the
basis for finding a treatment which was right for them and al-
lowed them to avoid pointless therapies.
So once the diagnosis is there, if I can put it that way, and there is
the option of having such tests before you start treatment to find988out how your body is likely to respond, I think it is a good option to
find the right tailored treatment for yourself. And not just simply
impose a sort of one-type-fits-all treatment. (RESP 4)
But patients also criticized gene expression analyses: some pa-
tients reported that the findings of the tests were difficult for lay
people to understand.
And three, four days later the results were there on a piece of pa-
per. And for the average Joe they might as well be written in Chi-
nese. (RESP 4)
A more fundamental criticism was that the test induced hopes
which could not be fulfilled. Thus, one patient reported that it
had been suggested to her that by carrying out the test she might
be able to avoid chemotherapy. The test results had then made it
clear that chemotherapy was necessary.
[Because of gene expression analyses, thatʼs right.] It was sup-
posed to find out whether the tumor would respond to hormone
treatment, which would actually save me from having to undergo
chemotherapy. And the whole time that is what I was assuming,
that would be my path, I will not have to do it. And after surgery
the values for the tumor which was removed during surgery and
the biopsy values were compared with one another. And then I was
just told that the values had not dropped to the extent they had
hoped. […] And then I just sat there: will we be doing chemother-
apy then? The residual risk without chemotherapy is 13%. (RESP 4)
Another patient who underwent preventive chemotherapy fol-
lowing the results of gene expression analyses reported that she
now had doubts about her decision and that she experienced che-
motherapy as extremely debilitating (RESP 8).
Expectations about the course of treatment
The interviewed patients reported numerous expectations about
gene expression analyses and the subsequent treatment based on
the analyses, particularly with regard to its timing, the sequence
of medical events and the interaction between physician and pa-
tient. In addition, a number of suggestions on improving medical
and organizational processes were put forward. With regard to
timing, all of the patients felt that it was important to not be
under time pressure and to have enough time between the diag-
nosis and the start of therapy to obtain a second opinion if they
wished and to get information about the therapy options.
I would say, the first physician was like that, he said to me: “Defi-
nitely remove the right breast. Well, there is no other alternative.”
And they very much suspected that the left side was also affected
and he would advise to have my MRI straight away, which would
have cost me 600 Euros. And then he gave me something to sign.
And then I said: “No, Iʼm not signing that.” So he was a bit af-
fronted. “Why?” […]. And I said: “Well, I want to look into it first,
get myself a second opinion”. (RESP 6)
The patients also expected that the physician would have enough
time for them and that decisions for or against a particular ther-Schleidgen S et al. How Do Patients… Geburtsh Frauenheilk 2017; 77: 984–992
apy would be made jointly (RESP 5). Most patients wanted to be
able to understand the findings of the gene expression tests as
this would allow them to assess the potential benefits of further
treatment. They therefore expect an extended briefing with a lot
of information on the test and an explanation of the analyses re-
sults and further treatment options (RESP 4). It was important for
them that physicians took enough time, that the physiciansʼ state-
ments were honest and comprehensible, and that the physicians
were able to dispel the patientʼs fears of potential treatment op-
tions. One patient stated that she expected the physician to take
her opinions seriously and encourage her. After being diagnosed
with breast cancer she had deliberately looked for a physician
who shared her opinions and her wish to have gene expression
analyses (RESP 8).
Another wish of patients related to improving organizational
procedures. One patient reported that she would have wished
for a coordinator to advise and support patients.
And in terms of registration, what is actually lacking is a person
who is there for the patients. Someone whom you could, I guess,
call when you say: “Oh, a test.” Right, the medical insurance com-
pany is not going to pay for that […]. And then I didnʼt know how
matters were going to continue. That means, should I approach
the health insurance company or write a letter to find out whether
the health insurance company would still fund it and so on.
Something like that, where a coordinator would have that in hand.
(RESP 6)
Another patient expressed the wish to receive (psychological)
support for her family members.
And I also think, at least that is how I feel, that it puts a big strain
on family members. (…). The kids arenʼt stressed that much, but
my husband, for example, is really suffering. And I donʼt know
what could be done to improve matters, so that they would sim-
ply, that they would also be supported or, yeah. (RESP 5)
Involvement in the patient briefing and the decision
about further treatment
In response to the question who had given the patient briefing, 6
patients reported that the physician treating them at the Breast
Center had informed them about the possibility of having gene
expression analyses. Two other patients were not informed by
the first physician who treated them about the possibility of hav-
ing gene expression analyses and only learned about them when
they obtained a second opinion or during an extensive internet
search (RESP 8).
The majority of patients felt that the briefing about gene ex-
pression analyses was largely positive. The interviewed patients
reported that they had been given sufficient information about
gene expression analyses. They had also generally been able to
understand the medical explanations. However, 2 patients re-
ported that, despite the efforts of the physicians, the patients
had felt that some of the information about gene expression anal-
yses was too complicated. They ascribed this to the specialist ter-
minology used and to the complexity of gene expression analyses.Schleidgen S et al. How Do Patients… Geburtsh Frauenheilk 2017; 77: 984–992In addition to receiving a comprehensible explanation of gene
expression analyses the interviewed patients also felt that involv-
ing their family and close friends in the patient briefing was im-
portant. Some of the patients took family members or people
from their circle of friends along to the discussions to ask ques-
tions about the information and the resulting treatment options
(RESP 6).
The patients were also asked who had taken the decision to
have gene expression analyses. Four patients reported that they
had taken the decision together with the physician treating them.
Two patients had taken the decision to have the test by them-
selves. Two patients had the impression that the physician treat-
ing them had taken the decision for them.
The patients also mentioned various reasons for deciding to
have gene expression analyses. All of the patients reported that
they had had gene expression analyses in the hope of being able
to avoid having chemotherapy.
And then there was also this possibility that I would be able to go
on without having chemotherapy. That was really decisive for me.
(RESP 5)
Five of the interviewed patients reported in addition that they
wanted to take part in the study as it would give them access to
the latest medical findings (RESP 1). One patient was encouraged
to participate in the study after talking with other breast cancer
patients.
And I also talked with patients who had formerly had breast can-
cer, they said: “Hey, a study program, do it.” (RESP 4)
Four of the interviewed patients additionally reported that they
hoped that the treatment they would receive after gene expres-
sion analyses would be more targeted.
And (…) it is simply the case that the more you know about such a
tumor, the more targeted the treatment can be and the more pre-
cisely one can say what is now needed and what is not. (RESP 1)
Seven patients reported that they had gene expression analyses
because they trusted their physicians and additionally assumed
that the physicians would choose the best available options and
treatments for them.
Right, so the stuff that I have experienced now from doctors, also
in terms of getting information in [hospital], I have such enormous
trust, and I know that that is the right path for me. I mean, there is
never a guarantee. But there is no guarantee if you have chemo-
therapy either. But now I just trust that everything is right for me.
(RESP 1)
The two patients who were not able to participate in the study re-
ported that they were dissatisfied with the care and treatment
they had received from the first physicians who had treated them.
This was why they had switched to the Breast Center where physi-
cians offered them the opportunity to have gene expression anal-
yses.989
GebFra Science |Original ArticleDiscussion
Given the current discussion about the benefits of gene expres-
sion analyses, this study aimed to look at the questions
1. how patients with breast cancer perceived such an individual-
ized molecular genomic approach and the treatment options
based on this analyses,
2. to what extent patients felt themselves included in the respec-
tive decisions on treatment, and
3. what hopes or expectations patients associated with such an
approach.
As regards the first question the study found that the interviewed
patients had different perceptions of what gene expression analy-
ses meant in terms of tailored medicine. One patient was of the
opinion that no truly tailored treatment existed as this would cor-
respond to treatment with 100% prospect of cure. This ultimately
correct assessment shows what expectations patients associate
with the term “tailored” treatment – and how big the risk is of fo-
menting disproportionate hopes about the absolute certainty of
curative therapies, particularly in the context of serious disease.
The other 7 patients (implicitly) differentiated between indi-
vidualized and tailored treatment strategies: they felt that individ-
ualized treatment was primarily distinguished by there being var-
ious treatment options while tailored treatment was considered
to be drug treatment specifically tailored to the individual patient
based on extensive diagnostic tests. Three patients considered
gene expression analyses a diagnostic test that would be required
for tailored treatment. However 4 patients considered gene ex-
pression analyses as a strategy which could be used to differenti-
ate between patient subgroups for which specific therapy options
were indicated, with gene expression analyses an important part
of stratifiedmolecular genomic medicine. What makes these opin-
ions interesting is that the understanding of individualized treat-
ment strategies falls far short of the claims which are currently
being posited for individualized treatment [2,15] and that any
type of treatment which includes different therapy options could
be referred to as individualized. In contrast, patientsʼ views of tai-
lored medicine appear to mirror the currently prevalent lines of
discussion. The fact that 3 of the interviewed patients understood
gene expression analyses to be part of a treatment strategy aimed
at the individual patient shows that the treatment concept is likely
to raise false hopes among some of the patients. The patients who
understood gene expression analyses as one element of stratified
therapeutic treatment had a far more realistic view and one which
corresponded more closely to the developments which are cur-
rently being promoted under the label of individualized medicine
[14,15].
Despite the differences in their understanding of individualized
or tailored medicine outlined above, what was very striking was
the overwhelmingly positive perception of gene expression analy-
ses and of the decisions based on the test outcomes: the analyses
could be used to select the appropriate treatment option for each
respective patient and avoid unnecessary treatment. The under-
standing of tailored treatment strategies therefore played, at
best, a minor role in the retrospective assessment of the treatment
they had received. What was more important was that gene ex-990pression analyses helped patients underpin their certainty about
their own subjective decision for or against treatment options.
This was also noted in other studies [26,27]. It was due to pa-
tientsʼ clearly expressed expectation of getting better treatment
following gene expression analyses, either because treatment
would be more targeted and therefore more effective or because
gene expression analyses would allow them to avoid having to
undergo debilitating therapy with many side effects and no po-
tential benefits. But these expectations can only be fulfilled if reli-
able information on the potential benefits and risks of biomarker-
based, stratified treatment strategies is available [10].
Only one patient criticized that it had been suggested to her
that by carrying out gene expression analyses she could avoid che-
motherapy – which had not been the case. The statements of this
interviewed patient indicated that she had erroneously assumed
that there was a causal connection between gene expression anal-
yses tests and avoiding chemotherapy, i.e., she had assumed that
the analyses themselves would be enough for her not have to have
chemotherapy. This misunderstanding points to our second re-
search question about the perception of being involved in thera-
peutic decisions and, in this connection, about the perceptions of
how patients had been briefed by physicians about gene expres-
sion analyses and the therapy decisions based on the analyses.
Although the patients largely rated the briefing and informa-
tion they had received as positive, two of the interviewed women
emphasized that the medical information was difficult for lay peo-
ple to understand and that the explanations were too compli-
cated. Nevertheless, all of the patients stated that they wanted
to hear the results of the gene expression analyses so that they
could assess their therapy options and make a decision together
with their physician. Several studies have shown that there is an
increasing tendency for patients with breast cancer to participate
actively in therapy decisions [31–33]. One study which looked at
the Prosigna test showed that patients with breast cancer who
were given the results of their gene expression tests were indeed
better informed and more able to participate in decision-making
and that their emotional and functional well-being was higher
[27]. But what was striking in our study was that only 4 patients
reported that they had really decided together with their treating
physician about their further course of treatment. In contrast,
2 patients stated that they had taken the decision alone and 2 sug-
gested that the decision for a specific treatment had only been
taken by the physicians. These statements emphasized the need
to further explore the opportunities and limits to joint decision-
making in complex medical contexts such as individualized mo-
lecular genomic medicine. But it is also conceivable that the dif-
ferent assessments may conceal different preferences with re-
spect to the patientʼs own role in the decision-making process.
As regards our third research question, in addition to the oppor-
tunity of joint decision-making the interviewed women expressed
a number of other hopes and expectations about treatment deci-
sions based on gene expression analyses: key expectations in-
cluded the hope that patientʼs individual needs would be taken in-
to account during treatment. Several patients also wished for
structured counseling for themselves and family members. These
statements show that the interviewed patients expected far more
than just differentiated molecular genomic treatment, i.e., thatSchleidgen S et al. How Do Patients… Geburtsh Frauenheilk 2017; 77: 984–992
they wished for individualized treatment in the broadest sense of
the term, treatment which would take patients seriously as indi-
vidual personalities. Ideally, as one patient hoped, the treating
physician would be of the same opinion as his patient with regard
to existing treatment options. Given the plurality of values and at-
titudes to life which exist in modern society this ideal will only
rarely be achieved. Instead the ethical requirement must be that
the physician is open to the different needs of his patient and sup-
ports his patient in choosing the type of treatment which is most
appropriate for the patientʼs individual situation and attitude to
life. But patients also need enough time to get a second opinion
if they want it, and to be supported by a person they trust. This
study once again highlights the challenge of taking psychosocial
aspects sufficiently into account during medical treatment, given
the ever increasing options of molecular genomic individualiza-
tion [16]; it is the only way in which so-called individualized med-
icine can fulfil what patients rightly expect: that their medical
treatment will be patient-oriented in the broadest sense of the
word.
Finally it should be noted that this empirical study has several
methodological limitations which need to be taken into account
when interpreting the results. One limitation of the study is its
small sample size. Despite intensive efforts and the involvement
of a gatekeeper only 8 patients could be recruited into the study
over a period of 1.5 years. This is probably due to the sensitive
topic of the analysis and the expected associated stress for study
participants, particularly in the immediate postoperative phase. It
would therefore be useful to carry out further studies into the per-
ception and assessment of individualized medical approaches
such as diagnostic gene expression analyses. As this study only in-
terviewed patients who had individualized treatment, future stud-
ies could focus on interviewing patients who underwent standard
treatment. This would allow the perception and assessment of
both treatment options to be compared, which would provide fur-
ther insight into treatment options from the patientsʼ point of
view. Similarly, the results of this explorative study could contrib-
ute to developing the appropriate quantitative survey instru-
ments.
A further limitation lies in the sample population itself. Most of
the patients who participated in the study were satisfied with the
process and implementation of gene expression analyses testing
and therefore had a positive view of gene expression analyses.
Only one patient had retrospective doubts about her decision.
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